AviadoBio just made three moves at once, and together they tell a story about a company that’s consolidating control and accelerating. The London-based gene therapy company has regained full rights to its lead program AVB-101, secured strategic funding from the Treat FTD Fund (backed by the Alzheimer’s Drug Discovery Foundation and the Association for Frontotemporal Degeneration), and initiated the fourth dose-escalation cohort in its Phase 1/2 ASPIRE-FTD trial. That’s a lot of news for one press release.

Let’s unpack the rights reacquisition first, because that’s the strategic headline. AviadoBio previously had an exclusive option and license agreement with Astellas Pharma, announced in October 2024 — a deal that came with a $20 million equity investment, up to $30 million in upfront payments, and milestone potential up to $2.18 billion. Getting full rights back, funded by a disease advocacy foundation rather than a pharma partner, suggests AviadoBio is betting on itself. They want to own the whole story.

AVB-101 itself remains one of the more ambitious gene therapy programs out there. It’s a one-time AAV gene therapy that delivers a functional copy of the GRN gene directly into the thalamus via stereotactic neurosurgery — bypassing the blood-brain barrier entirely. The goal is to restore progranulin expression in patients with frontotemporal dementia caused by GRN mutations (FTD-GRN), a devastating early-onset dementia that typically strikes between ages 45 and 68 and has no approved treatment.

The delivery innovation is key. Traditional gene therapy approaches get less than 1% of cortical neurons transduced. AviadoBio’s intrathalamic approach leverages the thalamus as a neurological hub with projections throughout the brain, achieving what preclinical studies showed as physiological levels of therapeutic protein across the entire brain. The trial has FDA Fast Track and orphan designations, is recruiting across six countries, and has shown no clinically significant safety findings through 52 weeks of follow-up in early cohorts — with no immunosuppression required.

The fourth cohort means higher doses, and biomarker data from across all cohorts is expected in the second half of 2026. Backed by NEA, F-Prime Capital, Monograph Capital, and now disease advocacy funding, AviadoBio is writing a playbook for what patient-community-funded gene therapy development can look like.